M
Mandana Nikpour
Researcher at University of Melbourne
Publications - 204
Citations - 4944
Mandana Nikpour is an academic researcher from University of Melbourne. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 33, co-authored 170 publications receiving 3637 citations. Previous affiliations of Mandana Nikpour include Toronto Western Hospital & University of Toronto.
Papers
More filters
Journal ArticleDOI
Definition and initial validation of a Lupus Low Disease Activity State (LLDAS)
Kate Franklyn,Chak Sing Lau,Sandra V. Navarra,Worawit Louthrenoo,Aisha Lateef,Laniyati Hamijoyo,C Singgih Wahono,Shun Le Chen,O Jin,S. Morton,Alberta Hoi,Molla Huq,Mandana Nikpour,Eric F Morand +13 more
TL;DR: A definition of LLDAS has been generated, and preliminary validation demonstrates its attainment to be associated with improved outcomes in SLE.
Journal Article
Premature atherosclerosis in systemic lupus ervthematosus
TL;DR: Current knowledge is sufficient to justify the belief that an aggressive approach to management of traditional CAD risk factors in patients with SLE is likely to have a major impact on morbidity and mortality in this population.
Journal ArticleDOI
Extent of disease on high-resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung disease
O. Moore,Nicole S L Goh,Tamera J. Corte,Hannah Rouse,Oliver Hennessy,Vivek Thakkar,J. Byron,Joanne Sahhar,Janet Roddy,Eli Gabbay,Peter Youssef,Peter Nash,Jane Zochling,Susanna Proudman,Susanna Proudman,Wendy Stevens,Mandana Nikpour,Mandana Nikpour +17 more
TL;DR: Extensive disease (>20%) on HRCT at baseline, reported using a semi-quantitative grading system, is associated with a three-fold increased risk of deterioration or death in SSc-ILD, compared with limited disease.
Journal ArticleDOI
Prevalence, correlates and clinical usefulness of antibodies to RNA polymerase III in systemic sclerosis: a cross-sectional analysis of data from an Australian cohort.
Mandana Nikpour,Mandana Nikpour,Pravin Hissaria,Pravin Hissaria,J. Byron,Joanne Sahhar,Maree Micallef,William Paspaliaris,Janet Roddy,Peter Nash,Alan Sturgess,Susanna Proudman,Wendy Stevens +12 more
TL;DR: Anti-RNAP status is a clinically useful prognostic marker in SSc and enables clinicians to identify patients at high risk of developing renal crisis, synovitis, myositis and joint contractures, as well as identifying patients with increased risk of malignancy within a 5-year timeframe before or after onset of SSc skin changes.
Journal ArticleDOI
Frequency and determinants of flare and persistently active disease in systemic lupus erythematosus.
TL;DR: Persistent activity is a common disease state in Lupus erythematosus and should be an outcome variable in SLE clinical trials, and the PAD prediction model may aid prognostication and selection of patients for inclusion in clinical trials.